// +author:a abbruzzese +author:abbruzzese 
var _ajax_res = {
  hits: 25,

  first: 0,

  results: [

{userid:"SEP", "refid":1418,"repocollections":"","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"The Association between the Chronotype and Cortisol Levels as well as Gene Expression Levels of hPER1 in the Evening","year":"2013","author":"Elvira A. Abbruzzese, Annina Klingmann, Ulrike Ehlert","journal":"International Journal of Advances in Psychology (IJAP)","volume":"2","number":"4","pages":"217-223","month":"11","doi":"","pubmed":"","pdflink":"http:\/\/www.ij-psychol.org\/Download.aspx?ID=1978","urllink":"http:\/\/www.ij-psychol.org\/paperInfo.aspx?ID=1978","abstract":"Humans usually show 24-hour sleep-wake cycles, which are geared by an inherent, interindividually varying biological clock. The behavioral daytime preferences differ according to the chronotype, which is in turn basically associated with the timing and controlling of the circadian rhythms of biological and psychological parameters. We were interested in the association between chronotype and the levels of cortisol and the clock gene hPER1 in the evening, and therefore examined 29 healthy men. Our data indicate that morning types show lower levels of cortisol and a lower gene expression of hPER1 in the evening.","note":"","tags":"Chronotype, Cortisol, hPER1, Evening Profile, Gene Expression, Biological Clock, Circadian Rhythm, SCN, Sleep","weight":1418}
,

{userid:"everardo", "articletype":"article","pages":"205-211","author":"Everardo D Saad, James L Abbruzzese","year":"2002","title":"Prognostic stratification in UPC: a role for assessing the value of conventional-dose and high-dose chemotherapy for unknown primary carcinoma.","month":"Feb","journal":"Crit Rev Oncol Hematol","publisher":"","volume":"41","number":"2","note":"","tags":"Adult,Antineoplastic Agents,Clinical Trials as Topic,Female,Humans,Male,Middle Aged,Neoplasms, Unknown Primary,Prognosis","booktitle":"","editor":"","abstract":"High-dose chemotherapy has been advocated by some investigators as a means to circumvent drug resistance, thereby improving treatment results in patients with solid tumors. For patients with unknown primary tumors, this hypothesis has only recently undergone limited testing. Two groups (one from the USA and one from Europe) have published their experience with higher doses of chemotherapy in the treatment of UPC. The results are not superior to those reported by other investigators using more standard doses of chemotherapy. Most importantly, chemotherapy trials for UPC are usually conducted in small populations made up of heterogeneous patient subsets with varying sensitivity to chemotherapy. It seems likely that progress in the management of patients with unknown primary cancers will occur as a result of efforts to improve the understanding of the natural history of this disease coupled with the assessment of novel agents targeted against specific biochemical abnormalities that will be demonstrated to be important in the development and maintenance of these malignancies.","address":"","school":"","issn":"1040-8428","doi":"","isi":"","pubmed":"11856596","key":"Saad2002","howpublished":"","urllink":"","refid":26}
,

{userid:"agostino.steffan", "articletype":"article","pages":"37-43","author":"A Da Ponte, E Bidoli, R Talamini, A Steffan, L Abbruzzese, R Tassan Toffola, L De Marco","year":"2005","title":"Pre-storage leucocyte depletion and transfusion reaction rates in cancer patients.","month":"Feb","journal":"Transfus Med","publisher":"","volume":"15","number":"1","note":"","tags":"Adolescent,Adult,Aged,Blood Preservation,Erythrocyte Transfusion,Female,Humans,Leukocyte Reduction Procedures,Male,Middle Aged,Neoplasms","booktitle":"","editor":"","abstract":"Passenger leucocytes transfused with allogenic blood are responsible for potential adverse effects. The impact of pre-storage leucodepletion (in-line filtration) of all whole blood units on transfusion reaction rate among patients suffering from cancer was retrospectively studied, comparing all reactions following red blood cell (RBC) transfusions during 2 years of pre-storage vs. 2 years of selective (bedside) leucodepletion. During selective leucodepletion, 5165 RBC units - of which 2745 were bedside filtered units- were transfused to 866 patients. Twenty-eight reactions were recorded: 22 (15 in the bedside group) febrile non-haemolytic transfusion reactions (FNHTR) and six allergic reactions (five in the bedside group). The overall percentage of reactions was 0.54 (0.76 for bedside) and 0.42 for FNHTR (0.54 for bedside). During pre-storage leucodepletion, 4116 RBC units were transfused to 841 patients. Eleven reactions were recorded: four FNHTR and seven allergic reactions (urticaria). The percentage of reactions for transfused RBC units was 0.26 (0.09 for FNHTR). Comparison between pre-storage filtration and bedside filtration with regard to FNHTR showed an odds ratio of 2.80 (95% confidence interval = 0.83-14.87) for bedside filtration. The study suggests that, for transfused patients affected by cancer, pre-storage leucodepletion is more effective than selective (bedside) filtration in reducing the incidence of transfusion reactions (FNHTR).","address":"","school":"","issn":"0958-7578","doi":"10.1111\/j.1365-3148.2005.00546.x","isi":"","pubmed":"15713127","key":"DaPonte2005","howpublished":"","urllink":"","refid":5}
,

{userid:"tassone", "articletype":"article","pages":"854-870","author":"P Tassone, P Tagliaferri, M Rossi, T Calimeri, A Bulotta, A Abbruzzese, M Caraglia, P Neri","year":"2009","title":"Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy.","month":"Nov","journal":"Curr Cancer Drug Targets","publisher":"","volume":"9","number":"7","note":"","tags":"Animals,Antineoplastic Agents,Bone Density Conservation Agents,Bone Neoplasms,Diphosphonates,Disease Models, Animal,Drug Delivery Systems,Humans,Mice,Mice, SCID,Models, Biological,Multiple Myeloma,Osteoblasts,Osteoclasts,Signal Transduction","booktitle":"","editor":"","abstract":"Bone disease (BD) is the hall-mark clinical feature of multiple myeloma (MM), accounting up to 60% of patients with bone pain at diagnosis and 60% with a pathologic fracture during the course of their disease. Experimental models, which recapitulate in vivo the human bone marrow microenvironment (HBMM) in immunodeficient mice have been recently developed as valuable tool for the study of MM pathophysiology as well as the experimental treatment of BD. At present, bisphosphonates are the mainstay treatment of MM-related BD. The growing information on the cellular and molecular bases of BD as well as the availability of novel anti-resorptive agents, such as the IgG1-anti-RANKL (AMG 161) Denosumab, are now depicting a new scenario where the treatment will be afforded by the use of different agents. Furthermore the availability of highthroughput molecular profiling approaches, including DNA microarrays and proteomics, is likely to provide new platforms for patients stratification and treatment individualization on specific targets. It is now the right time for a therapeutical approach which is rationally based on the complexity of the biopathology of MM-related BD.","address":"","school":"","issn":"1873-5576","doi":"","isi":"","pubmed":"20025573","key":"Tassone2009","howpublished":"","urllink":"","refid":80}
,

{userid:"nicola.perrotti", "refid":47,"repocollections":"","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"Determination of SGK1 mRNA in non-small cell lung cancer samples underlines high expression in squamous cell carcinomas.\r\n","year":"2012","author":"Abbruzzese C, Mattarocci S, Pizzuti L, Mileo AM, Visca P, Antoniani B, Alessandrini G, Facciolo F,\r\nAmato R, D'Antona L, Rinaldi M, Felsani A, Perrotti N, Paggi MG. \r\n","journal":"JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH","volume":"12","number":"","pages":"","month":"","doi":"","pubmed":"","pdflink":"","urllink":"","abstract":"","note":"","tags":""}
,

{userid:"tassone", "articletype":"article","pages":"757-765","author":"M Caraglia, M Marra, G Giuberti, A M D'Alessandro, A Baldi, P Tassone, S Venuta, P Tagliaferri, A Abbruzzese","year":"2003","title":"The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells.","month":"Jun","journal":"J Biochem","publisher":"","volume":"133","number":"6","note":"","tags":"Antineoplastic Agents,Apoptosis,Cell Division,Cell Line, Tumor,Dose-Response Relationship, Drug,Drug Combinations,Epidermal Growth Factor,Guanine,Humans,Interferon-alpha,KB Cells,Lysine,MAP Kinase Signaling System,Mitogen-Activated Protein Kinase 1,Mitogen-Activated Protein Kinase 3,Mitogen-Activated Protein Kinases,Peptide Initiation Factors,Phosphorylation,Protein Processing, Post-Translational,RNA-Binding Proteins","booktitle":"","editor":"","abstract":"Interferon-alpha (IFNalpha) can induce apoptosis, a process regulated by a complex network of cell factors. Among these, eukaryotic initiation factor-5A (eIF-5A) is peculiar because its activity is modulated by the post-translational formation of the amino acid hypusine. Here we report the effects of IFNalpha and epidermal growth factor (EGF) on apoptosis and eIF-5A activity in human epidermoid oropharyngeal KB and lung H1355 cancer cells. We found that 48-h exposure to 1000 and 2000 IU\/ml IFNalpha induced about 50% growth inhibition and apoptosis in H1355 and KB cells, respectively, and the addition of EGF completely antagonized this effect. When IFNalpha induced apoptosis, a hyperactivation of MEK-1 and ERK signalling and a decrease of the hypusine-containing form and, thus, of eIF-5A activity were recorded. The latter effect was again antagonized by the addition of EGF to IFNalpha-pretreated cells, probably through the activation of the EGF-->ERK-dependent pathway, since the addition of the specific MEK-1 inhibitor PD098059 abrogated the recovery of intracellular hypusine content induced by EGF in IFNalpha-pretreated cancer cells. Subsequently, we evaluated if the hypusine synthesis inhibitor (and eIF-5A inactivator) N1-guanyl-1,7-diaminoheptane (GC7) synergized with IFNalpha in the induction of cell growth inhibition and apoptosis. The analysis of the isobologram of IFNalpha and GC7 demonstrated a strong synergism between the two drugs in inducing cell growth inhibition. We also found that GC7 and IFNalpha had a synergistic effect on apoptosis. These data suggest that the apoptosis induced by IFNalpha could be regulated by eIF-5A that, therefore, could represent a useful target for the potentiation of IFNalpha antitumor activity.","address":"","school":"","issn":"0021-924X","doi":"","isi":"","pubmed":"12869532","key":"Caraglia2003","howpublished":"","urllink":"","refid":42}
,

{userid:"everardo", "articletype":"article","pages":"307-313","author":"Paulo M Hoff, Everardo D Saad, Richard Pazdur, Robert Wolff, Yvonne Lassere, Karla R Bogaard, James L Abbruzzese","year":"2004","title":"Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer.","month":"Aug","journal":"Invest New Drugs","publisher":"","volume":"22","number":"3","note":"","tags":"Adult,Aged,Antineoplastic Combined Chemotherapy Protocols,Camptothecin,Cohort Studies,Colorectal Neoplasms,Dose-Response Relationship, Drug,Drug Administration Schedule,Female,Humans,Male,Maximum Tolerated Dose,Middle Aged,Neoplasm Metastasis,Neutropenia,Organoplatinum Compounds,Treatment Outcome","booktitle":"","editor":"","abstract":"Both irinotecan and oxaliplatin are active agents in the treatment of patients with metastatic colorectal cancer (MCC). There is a strong preclinical rationale for combining these two agents. We sought to determine the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of combined irinotecan and oxaliplatin given every three weeks.","address":"","school":"","issn":"0167-6997","doi":"10.1023\/B:DRUG.0000026257.31142.41","isi":"","pubmed":"15122078","key":"Hoff2004","howpublished":"","urllink":"","refid":19}
,

{userid:"everardo", "articletype":"article","pages":"451-453","author":"Everardo D Saad, Eric H Kraut, Paulo M Hoff, Dennis F Moore, Donnah Jones, Richard Pazdur, James L Abbruzzese","year":"2002","title":"Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer.","month":"Oct","journal":"Am J Clin Oncol","publisher":"","volume":"25","number":"5","note":"","tags":"Aged,Antineoplastic Agents,Colorectal Neoplasms,Depsipeptides,Drug Administration Schedule,Female,Humans,Male,Middle Aged,Oligopeptides","booktitle":"","editor":"","abstract":"Dolastatin-10 is a potent inhibitor of microtubule assembly derived from the sea hare, which displayed significant antitumor activity in preclinical models. We conducted a phase II study of dolastatin-10 in patients with advanced colorectal cancer and no prior chemotherapy for metastatic disease. Fourteen patients received doses ranging from 300 microg\/m(2) to 450 microg\/m(2) as an intravenous push every 21 days. There were no major objective responses. Toxicity was mainly hematologic, with grade III or IV granulocytopenia occurring in 9 of 42 treatment courses. Other toxic effects were generally mild. Dolastatin-10 lacks clinically significant activity in advanced colorectal cancer when used in this dose and schedule.","address":"","school":"","issn":"0277-3732","doi":"","isi":"","pubmed":"12393982","key":"Saad2002","howpublished":"","urllink":"","refid":25}
,

{userid:"tassone", "articletype":"article","pages":"1-10","author":"Pierosandro Tagliaferri, Michele Caraglia, Alfredo Budillon, Monica Marra, Giovanni Vitale, Caterina Viscomi, Serena Masciari, Pierfrancesco Tassone, Alberto Abbruzzese, Salvatore Venuta","year":"2005","title":"New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer.","month":"Jan","journal":"Cancer Immunol Immunother","publisher":"","volume":"54","number":"1","note":"","tags":"Antineoplastic Agents,Apoptosis,Cell Cycle,Humans,Interferon-alpha,Models, Biological,Neoplasms,Signal Transduction","booktitle":"","editor":"","abstract":"Interferon alpha (IFN-alpha) has been widely used in the treatment of human solid and haematologic malignancies. Although the antitumour activity of IFN-alpha is well recognised at present, no major advances have been achieved in the last few years. Recent findings have provided new information on the molecular mechanisms of the antitumour activity of the cytokine. In fact, IFN-alpha appears to block cell proliferation, at least in part, through the induction of apoptotic effects. This cytokine can also regulate the progression of tumour cells through the different phases of the cell cycle inducing an increase of the expression of the cyclin-dependent kinase inhibitors p21 and p27. However, it must be considered that IFN-alpha is a physiologic molecule with ubiquitously expressed receptors that is likely to activate survival mechanisms in the cell. We have recently identified an epidermal growth factor (EGF) Ras-dependent protective response to the apoptosis induced by IFN-alpha in epidermoid cancer cells. The identification of tissue- and\/or tumour-specific survival pathways and their selective targeting might provide a new approach to improve the efficacy of IFN-alpha-based treatment of human cancer. Moreover, new pegylated species of IFN-alpha are now available with a more favourable pharmacokinetic profile. We will review these achievements, and we will specifically address the topic of IFN-alpha-based molecularly targeted combinatory antitumour approaches.","address":"","school":"","issn":"0340-7004","doi":"10.1007\/s00262-004-0549-1","isi":"","pubmed":"15693134","key":"Tagliaferri2005","howpublished":"","urllink":"","refid":34}
,

{userid:"tassone", "articletype":"article","pages":"1971-1978","author":"P Tassone, P Tagliaferri, C Viscomi, C Palmieri, M Caraglia, A D'Alessandro, E Galea, A Goel, A Abbruzzese, C R Boland, S Venuta","year":"2003","title":"Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro.","month":"Jun","journal":"Br J Cancer","publisher":"","volume":"88","number":"12","note":"","tags":"Apoptosis,Cell Division,Diphosphonates,Humans,Imidazoles,MAP Kinase Kinase 1,Mitogen-Activated Protein Kinase Kinases,Mitogen-Activated Protein Kinases,Pancreatic Neoplasms,Protein-Serine-Threonine Kinases,Proto-Oncogene Proteins c-raf,Tumor Cells, Cultured","booktitle":"","editor":"","abstract":"Bisphosphonates (BPs) are an emerging class of drugs mostly used in the palliative care of cancer patients. We investigated the in vitro activity of the most potent antiresorptive BP, zoledronic acid (ZOL), on the growth and survival of three human pancreatic cancer (PC) cell lines (BxPC-3, CFPAC-1 and PANC-1). Pancreatic cancer frequently has a dysregulated p21(ras) pathway and therefore appears to be a suitable target for BPs that interfere with the prenylation of small GTP-binding proteins such as p21(ras). We found that ZOL induces growth inhibition (IC(50):10-50 micro M) and apoptotic death of PC cells. The proapoptotic effect was correlated to cleavage\/activation of caspase-9 and poly(ADP)-ribose polymerase, but not of caspase-3. Moreover, we studied the p21(ras) signalling in cells exposed to ZOL and detected a reduction of p21(ras) and Raf-1 content and functional downregulation of the terminal enzyme ERK\/MAPkinase and of the pKB\/Akt survival pathway. Finally, we observed that ZOL induces significant cytoskeletal rearrangements. In conclusion, we demonstrated that ZOL induces growth inhibition and apoptosis on PC cells and interferes with growth and survival pathways downstream to p21(ras). These findings might be relevant for expanding application of BPs in cancer treatment.","address":"","school":"","issn":"0007-0920","doi":"10.1038\/sj.bjc.6600986","isi":"","pubmed":"12799645","key":"Tassone2003","howpublished":"","urllink":"","refid":43}
  ]
}

;
ajaxResultsLoaded(_ajax_res);